JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $45

JP Morgan analyst Tessa Romero has maintained an Overweight rating on Edgewise Therapeutics (NASDAQ: EWTX) and raised the price target from $34 to $45. This adjustment reflects a positive outlook for the company in the market.